NASDAQ:KITE - Kite Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$179.79 +179.79 (+∞)
(As of 10/19/2017)
Previous Close$179.79
Today's Range$179.79 - $179.79
52-Week Range$39.82 - $179.99
VolumeN/A
Average Volume1.65 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Receive KITE News and Ratings via Email

Sign-up to receive the latest news and ratings for KITE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:KITE
CUSIPN/A
Phone+1-310-8249999

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Kite Pharma (NASDAQ:KITE) Frequently Asked Questions

What is Kite Pharma's stock symbol?

Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."

How were Kite Pharma's earnings last quarter?

Kite Pharma Inc (NASDAQ:KITE) posted its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.75) by $0.05. The biopharmaceutical company earned $4.90 million during the quarter, compared to analyst estimates of $5.74 million. The firm's revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.54) earnings per share. View Kite Pharma's Earnings History.

Has Kite Pharma been receiving favorable news coverage?

News headlines about KITE stock have trended neutral recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kite Pharma earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the immediate future.

What other stocks do shareholders of Kite Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kite Pharma investors own include Juno Therapeutics (JUNO), Puma Biotechnology (PBYI), Gilead Sciences (GILD), bluebird bio (BLUE), Celgene (CELG), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Alibaba Group (BABA) and Micron Technology (MU).

Who are Kite Pharma's key executives?

Kite Pharma's management team includes the folowing people:
  • Arie S. Belldegrun, Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson, Chief Financial Officer
  • Cynthia M. Butitta, Chief Operating Officer
  • David Chang M.D. Ph.D., Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim, Executive Vice President - Business Development
  • Timothy L. Moore, Executive Vice President - Technical Operations
  • Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations
  • , Bio & Compensation - 
  • Jian Irish Ph.D., Senior Vice President - Supply Chain
  • , Bio & Compensation - 
  • Jeffrey Wiezorek M.D., Senior Vice President - Clinical Development
  • Shawn Cline Tomasello, Chief Commercial Officer

How do I buy shares of Kite Pharma?

Shares of KITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kite Pharma's stock price today?

One share of KITE stock can currently be purchased for approximately $179.79.

What is Kite Pharma's official website?

The official website for Kite Pharma is http://www.kitepharma.com.

How can I contact Kite Pharma?

Kite Pharma's mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company can be reached via phone at +1-310-8249999.


MarketBeat Community Rating for Kite Pharma (NASDAQ KITE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  702 (Vote Outperform)
Underperform Votes:  333 (Vote Underperform)
Total Votes:  1,035
MarketBeat's community ratings are surveys of what our community members think about Kite Pharma and other stocks. Vote "Outperform" if you believe KITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel